局限性前列腺癌有效性试验的核心结局集
通过系统综述与15例患者访谈得出79个结局,经118例患者和56名国际医护人员参与的三轮德尔菲调查及13名医护人员与8例患者的共识会议,最终确立含19个结局的核心结局集(COS),其中12个适用于所有干预,7个为干预特定结局;作者指出以英国为中心的参与者可能限制其国际通用性。
要点
- 最终核心结局集共19个结局,12个适用于所有干预,7个为干预特定结局。
- 12个通用结局包括前列腺癌死亡、全因死亡、局部复发、远处转移、疾病进展、需挽救治疗、总体生活质量、压力性尿失禁、排尿功能、肠道功能、大便失禁和性功能。
- 7个干预特定结局分别针对手术、主动监测、消融治疗和激素治疗。
核心结论
- 建立了适用于局限性前列腺癌所有干预有效性试验的核心结局集,应在所有局限性前列腺癌有效性试验中测量。
研究设计与样本
- 基于已发表的局限性前列腺癌有效性研究系统综述和15例前列腺癌患者半结构化访谈得出79个结局。
- 采用两阶段共识流程,涉及118例患者和56名国际医护人员(肿瘤专科护士、泌尿外科医生和肿瘤科医生)。
- 共识流程包括三轮德尔菲调查,随后召开由13名医护人员和8例患者参加的面对面共识小组会议。
主要发现
- 最终核心结局集包括19个结局。
- 12个结局适用于所有干预:前列腺癌死亡、全因死亡、局部疾病复发、远处疾病复发/转移、疾病进展、需挽救治疗、总体生活质量、压力性尿失禁、排尿功能、肠道功能、大便失禁和性功能。
- 7个为干预特定结局:围手术期死亡(手术)、手术切缘阳性(手术)、血栓栓塞性疾病(手术)、令人困扰或症状性尿道或吻合口狭窄(手术)、需治愈性治疗(主动监测)、治疗失败(消融治疗)和激素治疗副作用(激素治疗)。
临床怎么用
- 作者认为试验者应说明为什么该核心结局集不适用,默认立场不应是某国开发的核心结局集自动不适用于其他地方。
局限性
- 以英国为中心的参与者可能限制其其他国家的通用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio; which is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials. PATIENTS, SUBJECTS AND METHODS: A list of 79 outcomes was derived from a systematic review of published localised prostate cancer effectiveness studies and semi-structured interviews with 15 patients with prostate cancer patients. A two-stage consensus process involving 118 patients and 56 international healthcare professionals (HCPs; cancer specialist nurses, urological surgeons and oncologists) was undertaken, consisting of a three-round Delphi survey followed by a face-to-face consensus panel meeting of 13 HCPs and eight patients. RESULTS: The final COS included 19 outcomes. In all, 12 apply to all interventions: death from prostate cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, urinary function, bowel function, faecal incontinence, and sexual function. Seven were intervention-specific: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative treatment (active surveillance), treatment failure (ablative therapy), and side-effects of hormonal therapy (hormone therapy). The UK-centric participants may limit the generalisability to other countries, but trialists should reason why the COS would not be applicable. The default position should not be that a COS developed in one country will automatically not be applicable elsewhere. CONCLUSION: We have established a COS for trials of effectiveness in localised prostate cancer, applicable across all interventions that should be measured in all localised prostate cancer effectiveness trials.
引用
- MacLennan S, Williamson PR, Bekema H, et al. A core outcome set for localised prostate cancer effectiveness trials. BJU Int. 2017. PMID: 28346770. doi:10.1111/bju.13854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。